89bio
89bio is a clinical-stage biopharmaceutical company developing innovative therapies for liver and cardiometabolic diseases, including the investigational FGF21 analog pegozafermin.
Last updated September 15, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
89bio is a clinical-stage biopharmaceutical company dedicated to developing and delivering innovative therapies to treat patients with liver and cardiometabolic diseases. The company uses its knowledge of FGF21 as a master metabolic regulator to develop innovative therapies, aiming to deliver potential treatments for patients who currently have no approved or limited treatment options. Its lead candidate, pegozafermin, is an investigational glycopegylated FGF21 analog being evaluated for metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). The company's primary location is in San Francisco, California, United States, with a satellite office in Rehovot, Israel. In September 2025, 89bio announced an agreement to be acquired by Roche.
History
89bio is a clinical-stage biopharmaceutical company dedicated to developing and delivering innovative therapies to treat patients with liver and cardiometabolic diseases. The company uses its knowledge of FGF21 as a master metabolic regulator to develop innovative therapies for liver and cardiometabolic diseases. Its lead candidate, pegozafermin, is an investigational glycopegylated FGF21 analog currently being evaluated for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). The company's primary location is in San Francisco, California, United States, with a satellite office in Rehovot, Israel. On September 18, 2025, 89bio, Inc. announced an agreement to be acquired by Roche.
Products and positioning
Clinical-stage biopharmaceutical company focused on liver and cardiometabolic diseases, using knowledge of FGF21 as a master metabolic regulator.
pegozafermin
Investigational glycopegylated FGF21 analog currently being evaluated for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG).
Sources3 sources
Cite this profile: Cite the canonical profile. /brand-wiki/89bio · Editorial policy · How profiles are compiled